NicholasJohnSarlisMDPhD, FACP

Summary

• As Chief Medical Officer (CMO) at CLEARA Biotech, N.V., my remit is to progress the company's compounds against 'scarred senescence'-driven malignancies, leveraging my expertise in clin. development, clin. trials, Med Affairs, Translational Oncology, and Scientific Comms. I also participate in BD&L activities, offer clin. study medical monitor services, interact with external experts (KOLs) and the Co's Supervisory Board, and manage CLEARA's Sci. Ad. Board.
  Before this role, I was CMO of The Lynx Group, LLC and then Head of Global Medical Content at Amplity Health, Inc. Prior to these engagements, I served as Executive VP and CMO - and then under contract Senior Advisor - at SELLAS Life Sciences Group, Inc. (NASDAQ, SLS), providing strategic insight on the direction of the clin. development programs for novel product candidates: peptide-based oncovaccines targeting Wilms Tumor-1 (WT1) [galinpepimut-S or GPS] and HER2 [nelipepimut-S or NPS/NeuVax] and a CDK9 inhibitor (SLS009). Prior to that role, I was heading Med. Affairs at Incyte Corp., initially in the US and then globally, supporting the launch of the original JAK inhibitor, ruxolitinib, and the IDO1 inhibitor, epacadostat. Before Incyte, held roles of increasing responsibility at Sanofi-Aventis (both in the US and globally) supporting Med Affairs.
  
  Before my stints in industry, I was Senior Clin. Investigator at NIH and then Assoc. Professor of Medicine at the MD Anderson Cancer Center. I received my M.D. degree and a Dr.Med.Sci. (Pharmacology) from the U. of Athens, GR, and my Ph.D. from the U. of London (UK), having completed superb clinical & basic training in the UK and the US.
  
  I am a Member or elected Fellow of various professional and learned societies, have received various awards, and serve as an Assoc. Editor of the J. Transl. Med. and JHOP. I have published 130+ papers, mainly with an oncology focus. I give presentations regularly in various industry and medical leadership forums worldwide.
CLEARA's approach to cancer metastasis mitigation and control.
Features of 'scarred' senescent -yet hyperproliferative- cancer cells within metastases, CLEARA targets these cells via peptides that disrupt FOXO4-p53 binding.

Cleara Biotech
Through detailed understanding of the molecular and biological pathways that underlie these individual pathological phenotypes, we set up disruptive, innovative